Phase 3, randomized trial (CheckMate 057) of nivolumab vs docetaxel in advanced non-squamous (non-SQ) non-small cell lung cancer (NSCLC): subgroup analyses and patient reported outcomes (PROs)

被引：0

作者：

Horn, L. ^{[1
]}

Brahmer, J. ^{[2
]}

Reck, M. ^{[3
]}

Borghaei, H. ^{[4
]}

Spigel, D. R. ^{[5
]}

Steins, M. ^{[6
]}

Ready, E. ^{[7
]}

Chow, L. Q. ^{[8
]}

Vokes, E. E. ^{[9
]}

Felip, E. ^{[10
]}

Holgado, E. ^{[11
]}

Barlesi, F. ^{[12
]}

Kohlhaeufl, M. ^{[13
]}

Burgio, M. A. ^{[14
]}

Fayette, J. ^{[15
]}

Gettinger, S. N. ^{[16
]}

Harbison, C. T. ^{[17
]}

Li, A. ^{[18
]}

Finckenstein, F. G. ^{[19
]}

Paz-Ares, L. ^{[20
]}

机构：

[1] Vanderbilt Ingram Canc Ctr, Dept Med, Nashville, TN USA

[2] Johns Hopkins Univ Hosp, Sidney Kimmel Comprehens Canc Ctr, Baltimore, MD 21287 USA

[3] LungenClin Grosshansdorf, Grosshansdorf, Germany

[4] Fox Chase Canc Ctr, Med Oncol, Philadelphia, PA 19111 USA

[5] Sarah Cannon Res Inst, Ctr Canc, Med Oncol, Nashville, TN USA

[6] Thoraxklin Heidelberg, Internal Med Oncol, Heidelberg, Germany

[7] Duke Univ, Med Ctr, Div Oncol, Durham, NC USA

[8] Univ Washington, Dept Med, Seattle Canc Care Alliance, Seattle, WA USA

[9] Univ Chicago, Med Ctr, Dept Med, Chicago, IL 60637 USA

[10] Vall dHebron Univ Hosp, Dept Oncol, Barcelona, Spain

[11] Hosp Madrid Norte, San Chinarro Ctr Integral Oncol Clara Campal, Serv Oncol, Madrid, Spain

[12] Hop Nord Marseille, Multidisciplinary Oncol & Therapeut Innovat, Marseille, France

[13] Klin Schillerhohe, Pneumonol & Pulm Oncol, Gerlingen, Germany

[14] Ist Sci Romagnolo Studio & Cura Tumori, Dept Med Oncol, Meldola, Italy

[15] Ctr Leon Berard, Oncol Med, F-69373 Lyon, France

[16] Yale Univ, Sch Med Med Oncol, Med Oncol, New Haven, CT USA

[17] Bristol Myers Squibb Co, ImmunoSci Metab Dis & Fibrosis, Princeton, NJ USA

[18] Bristol Myers Squibb Co, Oncol, Princeton, NJ USA

[19] Bristol Myers Squibb Co, Oncol Global Clin Res, Princeton, NJ USA

[20] Hosp Univ Virgen del Rocio, Serv Oncol Med, Seville, Spain

来源：

ANNALS OF ONCOLOGY | 2015年 / 26卷

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

417O

引用

页码：125 / 125

页数：1

共 50 条

[1] Phase 3, randomized trial (CheckMate 057) of nivolumab (NIVO) vs docetaxel (DOC) in advanced non-squamous (non-SQ) non-small cell lung cancer (NSCLC): Subgroup analyses and patient reported outcomes (PROs)
Horn, L.
Brahmer, J.
Reck, M.
Borghaei, H.
Spigel, D. R.
Steins, M.
Ready, N. E.
Chow, L. Q.
Vokes, E. E.
Felip, E.
Holgado, E.
Barlesi, F.
Kohlhaeufl, M. J.
Burgio, M. A.
Fayette, J.
Gettinger, S. N.
Harbison, C. T.
Li, A.
Finckenstein, F. G.
Paz-Ares, L.
EUROPEAN JOURNAL OF CANCER, 2015, 51 : S599 - S599
[2] Phase 3, randomized trial (CheckMate 057) of nivolumab (NIVO) vs. docetaxel (DOC) in advanced non-squamous (non-SQ) non-small cell lung cancer (NSCLC) - subgroup analyses and patient reported outcomes (PROs)
Horn, L.
Brahmer, J.
Reck, M.
Borghaei, H.
Spigel, D.
Steins, M.
Ready, N.
Chow, L.
Vokes, E.
Felip, E.
Holgado, E.
Barlesi, F.
Kohlhaeufl, M.
Burgio, M.
Fayette, J.
Gettinger, S.
Harbison, C.
Li, A.
Finckenstein, F.
Paz-Ares, L.
ONCOLOGY RESEARCH AND TREATMENT, 2016, 39 : 27 - 27
[3] Phase III, randomized trial (CheckMate 057) of nivolumab (NIVO) versus docetaxel (DOC) in advanced non-squamous cell (non-SQ) non-small cell lung cancer (NSCLC).
Paz-Ares, Luis
Horn, Leora
Borghaei, Hossein
Spigel, David R.
Steins, Martin
Ready, Neal
Chow, Laura Quan Man
Vokes, Everett E.
Felip, Enriqueta
Holgado, Esther
Barlesi, Fabrice
Kohlhaeufl, Martin
Rodriguez, Oscar
Burgio, Marco Angelo
Fayette, Jerome
Gettinger, Scott N.
Harbison, Christopher
Dorange, Cecile
Finckenstein, Friedrich Graf
Brahmer, Julie R.
JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
[4] Phase III, randomized trial (CheckMate 057) of nivolumab (NIVO) versus docetaxel (DOC) in advanced non-squamous cell (non-SQ) non-small cell lung cancer (NSCLC)
Paz-Ares, Luis
Horn, Leora
Borghaei, Hossein
Spigel, David R.
Steins, Martin
Ready, Neal
Chow, Laura Quan Man
Vokes, Everett E.
Felip, Enriqueta
Holgado, Esther
Barlesi, Fabrice
Kohlhaeufl, Martin
Rodriguez, Oscar
Burgio, Marco Angelo
Fayette, Jerome
Gettinger, Scott N.
Harbison, Christopher
Dorange, Cecile
Finckenstein, Friedrich Graf
Brahmer, Julie R.
JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (18)
[5] Phase 3, Randomized Trial (CheckMate 017) of Nivolumab (NIVO) vs Docetaxel in Advanced Squamous (SQ) Cell Non-Small Cell Lung Cancer (NSCLC)
Reckamp, Karen
Brahmer, Julie R.
Spigel, David R.
Rizvi, Naiyer A.
Poddubskaya, Elena
West, Howard
Eberhardt, Wilfried E. E.
Baas, Paul
Antonia, Scott J.
Pluzanski, Adam
Vokes, Everett
Holgado, Esther
Waterhouse, David
Ready, Neal
Gainor, Justin F.
Aren Frontera, Osvaldo
Horn, Leora
Paz-Ares, Luis
Li, Ang
Lynch, Mark
JOURNAL OF THORACIC ONCOLOGY, 2015, 10 (09) : S174 - S175
[6] PHASE 3, RANDOMIZED TRIAL (CHECKMATE 017) OF NIVOLUMAB (NIVO) VS DOCETAXEL IN ADVANCED SQUAMOUS (SQ) CELL NON-SMALL CELL LUNG CANCER (NSCLC)
Rechamp, Karen
Spigel, David R.
Rizvi, Naiyer
Poddubskaya, Elena
West, Howard
Eberhardt, Wilfried
Baas, Paul
Antonia, Scott J.
Pluzanski, Adam
Vokes, Everett E.
Holgado, Esther
Waterhouse, David
Reddy, Neal
Gainor, Justin
Frontera, Osvaldo Aren
Horn, Leora
Paz-Ares, Luis
Zhu, Jin
Lynch, Mark
Brahmer, Julie
Asia-Pacific Journal of Clinical Oncology, 2015, 11 : 130 - 130
[7] CheckMate 078: Patient-Reported Outcomes (PROs) With Nivolumab vs Docetaxel in Advanced Non-Small Cell Lung Cancer (NSCLC)
Wu, Y.
Chang, J.
Zhang, L.
Tu, H.
Wu, L.
Feng, J.
Lu, S.
Zhou, C.
Wang, J.
Mok, T.
Taylor, F.
Mossman, B.
Penrod, J.
Lawrance, R.
Blum, S.
Wang, P. F.
Cheng, Y.
JOURNAL OF THORACIC ONCOLOGY, 2018, 13 (12) : S1047 - S1048
[8] Phase II studies of Nivolumab in patients with Advanced Squamous (SQ) or Non-Squamous (NSQ) Non-Small Cell Lung Cancer (NSCLC)
Sakai, H.
Nishio, M.
Hida, T.
Nakagawa, K.
Nogami, N.
Atagi, S.
Takahashi, T.
Nokihara, H.
Saka, H.
Takenoyama, M.
Fujita, S.
Tanaka, H.
Takeda, K.
Satouchi, M.
Isobe, H.
Maemondo, M.
Goto, K.
Hirashima, T.
Minato, K.
Tamura, T.
EUROPEAN JOURNAL OF CANCER, 2015, 51 : S110 - S111
[9] Analysis of Early Survival in Patients with Advanced Non-Squamous NSCLC Treated with Nivolumab vs Docetaxel in CheckMate 057
Peters, Solange
Cappuzzo, Frederico
Horn, Leora
Paz-Ares, Luis
Borghaei, Hossein
Barlesi, Fabrice
Steins, Martin
Felip, Enriqueta
Spigel, David
Dorange, Cecile
Lu, Haolan
Healey, Diane
Sanchez, Teresa Kong
Bhagavatheeswaran, Prabhu
Novotny, James, Jr.
Lestini, Brian
Brahmer, Julie
JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (01) : S253 - S253
[10] LCSS as a Marker of Treatment Benefit With Nivolumab vs Docetaxel in Pts With Advanced Non-Squamous NSCLC From Checkmate 057
Gralla, Richard J.
Spigel, David
Bennett, Bryan
Taylor, Fiona
Penrod, John R.
Derosa, Michael
Dastani, Homa
Orsini, Lucinda
Mathias, Clarissa
Reck, Martin
JOURNAL OF THORACIC ONCOLOGY, 2016, 11 (10) : S171 - S171

← 1 2 3 4 5 →